Drug interactions
Doxorubicin + Ponatinib
Severity: Moderate
Doxorubicin and Ponatinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ponatinib inhibits P-glycoprotein and BCRP in vitro, which may raise systemic exposure to doxorubicin, a substrate of these efflux transporters. Higher anthracycline levels could increase myelosuppression and cardiotoxicity. Ponatinib itself carries cardiovascular and cardiac failure risk, which adds to the concern.
What this interaction means in plain words
Doxorubicin and Ponatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Doxorubicin belongs to Oncology; Ponatinib belongs to Oncology.
Why it happens
Ponatinib inhibits P-gp/BCRP efflux transport, reducing doxorubicin efflux and clearance.
What to do
Monitor blood counts and cardiac function (including left ventricular ejection fraction) closely during combined use. Consider doxorubicin dose reduction if toxicity emerges.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Doxorubicin and Ponatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Doxorubicin
Other interactions of Ponatinib
Frequently asked questions
Can I take Doxorubicin with Ponatinib?
MediHelp rates the interaction as moderate. Doxorubicin and Ponatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ponatinib inhibits P-glycoprotein and BCRP in vitro, which may raise systemic exposure to doxorubicin, a substrate of these efflux transporters. Higher anthracycline levels could increase myelosuppression and cardiotoxicity. Ponatinib itself carries cardiovascular and cardiac failure risk, which adds to the concern.
How serious is the interaction between Doxorubicin and Ponatinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and cardiac function (including left ventricular ejection fraction) closely during combined use. Consider doxorubicin dose reduction if toxicity emerges.
What other medicines interact with Doxorubicin?
MediHelp also lists interactions of Doxorubicin with, for example, Adenovirus types 4 and 7 live, Belatacept, Cobicistat. The full list is on the Doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
